Sirtex trial better than expected

When Sirtex released the preliminary results of a major clinical trial a few weeks ago, investors fled – but new data suggests it wasn't so bad after all.

In Are Sirtex’s best days behind it? from 23 Apr 15 (Hold – $22.96), we made the case that while Sirtex Medical’s latest clinical trial result could have been better, it wasn’t as bad as it seemed.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles